Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | IDO1 | P14902 | 1/20 | 0.45 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.44 |
| ▸ | AGXT | P21549 | 1/20 | 0.43 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.43 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.43 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28808708 | 0.85 | PARP10 (0.45) | PARP10ALDH1A1NPC1RAB9AKMT2A | |
| SCHEMBL27726414 | 0.81 | ALDH1A1 (0.48) | PARP10ALDH1A1NPC1RAB9AKMT2A | |
| SCHEMBL27705810 | 0.81 | PARP10 (0.45) | PARP10ALDH1A1NPC1RAB9AKMT2A | |
| SCHEMBL28063042 | 0.81 | ALDH1A1 (0.48) | PARP10ALDH1A1NPC1RAB9AKMT2A | |
| SCHEMBL7667460 | 0.79 | ALDH1A1 (0.47) | PARP10ALDH1A1NPC1RAB9AKMT2A | |
| SCHEMBL5320045 | 0.79 | PARP10 (0.44) | PARP10ALDH1A1NPC1RAB9AKMT2A | |
| SCHEMBL16096077 | 0.76 | ALDH1A1 (0.47) | PARP10ALDH1A1NPC1RAB9AKMT2A | |
| SCHEMBL8316594 | 0.75 | ALDH1A1 (0.50) | ALDH1A1NPC1RAB9AKMT2AMAPK1 | |
| SCHEMBL27576689 | 0.74 | ALDH1A1 (0.55) | ALDH1A1NPC1RAB9AKMT2AMAPK1 | |
| SCHEMBL23616312 | 0.74 | L3MBTL1 (0.44) | PARP10ALDH1A1NPC1RAB9AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114478541-B | Method for synthesizing imidazo [4,5-b ] indole-2-thione derivative in metal-free catalytic system | 南京林业大学 | 2023-08-29 | — | — | CN | disclosed |
| CN-114478541-A | Method for synthesizing imidazo [4,5-b ] indole-2-thioketone derivative in metal-free catalytic system | 南京林业大学 | 2022-05-13 | — | — | CN | disclosed |
| CN-109824668-A | The polymorphic forms and pseudopolymorphic forms of medical compounds | 辉瑞爱尔兰制药公司 | 2019-05-31 | — | — | CN | disclosed |
| US-20170210742-A1 | NOVEL CRYSTALLINE FORMS OF TRANS-7-OXO-6-(SULPHOOXY)-1,6-DIAZABICYCLO[3,2,1]OCTANE-2-CARBOXAMIDE SODIUM SALT | FOREST LABORATORIES HOLDINGS LTD (BM) | 2017-07-27 | — | — | US | disclosed |
| US-9580424-B2 | Crystalline forms of trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide sodium salt | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2017-02-28 | — | — | US | disclosed |
| CN-102834395-B | Polymorphic and pseudopolymorphic forms of a pharmaceutical compound | 阿斯利康控股法国有限公司 | 2016-06-29 | — | — | CN | disclosed |
| US-20150246920-A1 | NOVEL CRYSTALLINE FORMS OF TRANS-7-OXO-6-(SULPHOOXY)-1,6-DIAZABICYCLO[3,2,1]OCTANE-2-CARBOXAMIDE SODIUM SALT | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2015-09-03 | — | — | US | disclosed |
| US-9062053-B2 | Crystalline forms of trans-7-oxo-6-(sulphooxy)-1,6-Diazabicyclo[3,2,1]octane-2-carboxamide sodium salt | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2015-06-23 | — | — | US | disclosed |
| CN-104592229-A | Polymorphic and pseudopolymorphic forms of a pharmaceutical compound | ASTRA ZENECA HOLDING FRANCE SAS | 2015-05-06 | — | — | CN | disclosed |
| US-20140349967-A1 | NOVEL CRYSTALLINE FORMS OF TRANS-7-OXO-6-(SULPHOOXY)-1,6-DIAZABICYCLO[3,2,1]OCTANE-2-CARBOXAMIDE SODIUM SALT | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2014-11-27 | — | — | US | disclosed |
| US-8835455-B2 | Crystalline forms of trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide sodium salt | ALLERGAN PHARMACEUTICALS INTERNATIONAL LIMITED (IE) | 2014-09-16 | — | — | US | disclosed |
| US-20130267480-A1 | NOVEL CRYSTALLINE FORMS OF TRANS-7-OXO-6-(SULPHOOXY)-1,6-DIAZABICYCLO[3,2,1]OCTANE-2-CARBOXAMIDE SODIUM SALT | ALLERGAN PHARMACEUTICALS INTERNATIONAL LIMITED (IE) | 2013-10-10 | — | — | US | disclosed |
| US-8471025-B2 | Crystalline forms of trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide sodium salt | ALLERGAN PHARMACEUTICALS INTERNATIONAL LIMITED (IE) | 2013-06-25 | — | — | US | disclosed |
| CN-102834395-A | Polymorphic and pseudopolymorphic forms of a pharmaceutical compound | NOVEXEL SA | 2012-12-19 | — | — | CN | disclosed |
| US-20110152311-A1 | NOVEL CRYSTALLINE FORMS OF TRANS-7-OXO-6-(SULPHOOXY)-1,6-DIAZABICYCLO[3,2,1]OCTANE-2-CARBOXAMIDE SODIUM SALT | FOREST LABORATORIES HOLDINGS LTD. (BM) | 2011-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110152311-A1 | NOVEL CRYSTALLINE FORMS OF TRANS-7-OXO-6-(SULPHOOXY)-1,6-DIAZABICYCLO[3,2,1]OCTANE-2-CARBOXAMIDE SODIUM SALT | SLC10A6, SLC5A2, SLC5A1 | PARP10 4527/4885ALDH1A1 4203/4885NPC1 3027/4885 |
| US-20130267480-A1 | NOVEL CRYSTALLINE FORMS OF TRANS-7-OXO-6-(SULPHOOXY)-1,6-DIAZABICYCLO[3,2,1]OCTANE-2-CARBOXAMIDE SODIUM SALT | SLC10A6, SLC5A2, SLC5A1 | PARP10 4527/4885ALDH1A1 4203/4885NPC1 3027/4885 |
| US-20170210742-A1 | NOVEL CRYSTALLINE FORMS OF TRANS-7-OXO-6-(SULPHOOXY)-1,6-DIAZABICYCLO[3,2,1]OCTANE-2-CARBOXAMIDE SODIUM SALT | SLC10A6, SLC5A2, SLC5A1 | PARP10 4527/4885ALDH1A1 4203/4885NPC1 3027/4885 |
| US-20140349967-A1 | NOVEL CRYSTALLINE FORMS OF TRANS-7-OXO-6-(SULPHOOXY)-1,6-DIAZABICYCLO[3,2,1]OCTANE-2-CARBOXAMIDE SODIUM SALT | SLC10A6, SLC5A2, SLC5A1 | PARP10 4527/4885ALDH1A1 4203/4885NPC1 3027/4885 |
| US-20150246920-A1 | NOVEL CRYSTALLINE FORMS OF TRANS-7-OXO-6-(SULPHOOXY)-1,6-DIAZABICYCLO[3,2,1]OCTANE-2-CARBOXAMIDE SODIUM SALT | SLC10A6, SLC5A2, SLC5A1 | PARP10 4527/4885ALDH1A1 4203/4885NPC1 3027/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.